Collaboration will leverage NVIDIA’s accelerated computing and AI technologies to advance therapeutic discovery, molecular design, and gene therapy research
Cambridge, Massachusetts— 25th,May,2026— CellantraTech, a biotechnology company focused on developing next-generation therapies for cancer and genetic diseases, today announced that it has entered into a strategic agreement with NVIDIA to leverage advanced artificial intelligence and accelerated computing technologies in support of the Company’s cancer drug discovery and gene therapy programs.
Under the agreement, CellantraTech intends to use NVIDIA’s AI and accelerated computing capabilities to enhance multiple stages of therapeutic research and development, including biological data analysis, target identification, molecular design, therapeutic candidate optimization, and the development of next-generation gene therapy approaches.
The collaboration is designed to combine CellantraTech’s expertise in oncology / genomics / gene therapy / precision medicine with NVIDIA’s leadership in accelerated computing and AI. The companies expect the initiative to help shorten computational research cycles, analyze complex biological datasets at greater scale, and improve the efficiency with which promising therapeutic candidates can be identified and evaluated.
“AI is transforming how new medicines can be discovered and developed,” said Eric, Chief Executive Officer of CellantraTech. “Our agreement with NVIDIA represents an important step in building an AI-enabled research platform capable of addressing some of the most difficult challenges in cancer and genetic disease. By combining our therapeutic expertise with NVIDIA’s advanced computing technologies, we believe we can accelerate the path from biological insight to potential new medicines.”
CellantraTech plans to apply the technology initially across specific cancer programs, gene therapy programs, target classes, or disease areas, with the potential to expand its use across the Company’s broader research pipeline.
The initiative may include the application of AI models to genomic and multi-omics datasets, protein and molecular modeling, therapeutic design, biomarker discovery, and optimization of gene therapy vectors and delivery strategies. These computational capabilities are expected to complement CellantraTech’s existing laboratory, translational, and clinical development infrastructure.
“Combining accelerated computing with large-scale biological data has the potential to fundamentally change therapeutic research,” said Catherine at NVIDIA.
The agreement also supports CellantraTech’s broader strategy to establish an integrated AI-enabled drug development platform that connects computational discovery with experimental validation and therapeutic development.
About CellantraTech
CellantraTech is a preclinical-stage biotechnology company developing innovative therapies for cancer and genetic diseases. The Company combines [AI, genomics, precision medicine, gene editing, drug discovery, or other core capabilities] to identify and develop differentiated therapeutic candidates addressing areas of significant unmet medical need.
For more information, visit [Company Website].
About NVIDIA
NVIDIA is a global leader in accelerated computing and artificial intelligence. Additional information about NVIDIA is available through the company’s official corporate communications channels.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the anticipated benefits of CellantraTech’s agreement with NVIDIA, the potential application of artificial intelligence and accelerated computing to the Company’s research and development activities, the advancement of cancer drug and gene therapy programs, and the potential development of therapeutic candidates.
Forward-looking statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied by such statements. Factors that could cause actual results to differ include scientific, technological, regulatory, clinical, commercial, and other risks associated with biotechnology and therapeutic development. CellantraTech undertakes no obligation to update these forward-looking statements except as required by applicable law.
Media and Investor Contact
[Name]
[Title]
CellantraTech
[Email]
[Phone]
[Website]
